SPHERE GENE THERAPEUTICS
DEAD

Serial Number

97410265

Owner

Sphere Gene Therapeutics Inc.

Attorney

Karen Won

Filing Date

May 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SPHERE GENE THERAPEUTICS Trademark

Serial Number: 97410265

SPHERE GENE THERAPEUTICS is a trademark filed by Sphere Gene Therapeutics Inc. on May 13, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Sphere Gene Therapeutics Inc.

1770 Massachusetts Ave., #810
Cambridge, MA 02140

Entity Type: 03

Trademark Details

Filing Date

May 13, 2022

Registration Date

Not Registered

Goods & Services

Biological preparations, namely, gene therapies based on engineered viral vectors, for preventing, managing and treating diseases and disorders of the liver, heart, skeletal muscle, ear, eye, peripheral and central nervous systems; Biological components in the nature of enveloped or membrane-associated viral vectors used for the delivery of therapeutic agents to targeted cells within the human body; Biological components in the nature of engineered viral vectors used for the delivery of therapeutic agents to targeted cells within the human body; Biological components, namely, viral vectors, being a component in therapeutic preparations for use in diseases and disorders of the liver, heart, skeletal muscle, ear, eye, peripheral and central nervous systems; Therapeutic agents and gene therapies based on engineered viral vectors for the treatment of diseases and disorders of the liver, heart, skeletal muscle, ear, eye, peripheral and central nervous system

Research and development in the fields of gene therapy based on engineered viral vectors, enveloped or membrane-associated viral vectors and engineered viral vectors; Providing scientific testing services in the medical fields of gene therapy based on engineered viral vectors, enveloped or membrane-associated viral vectors and engineered viral vectors; Providing medical scientific research information in the fields of gene therapy based on engineered viral vectors, enveloped or membrane-associated viral vectors and engineered viral vectors

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Aug 20, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Aug 20, 2025 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
May 3, 2025 GNFN
FINAL REFUSAL E-MAILED
May 3, 2025 GNFR
FINAL REFUSAL WRITTEN
May 3, 2025 CNFR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 16, 2025 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 27, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 27, 2024 GNSL
SUSPENSION LETTER WRITTEN
Feb 27, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 16, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 6, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 6, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 14, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jul 14, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jul 14, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 2, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 18, 2022 NWOS
NEW APPLICATION ENTERED
May 17, 2022 NWAP